Bristol-Myers has continued its efforts towards expanding its new product range, in-line franchises, pipeline, and carried out critical business growth initiatives. The company’s revenues for the second quarter reached approximately $11.9 billion, up 5% from the same period last year and surpassed Wall Street expectations. This result was fuelled by their in-line and new product portfolio's 16% solid growth, which more than made up for their recent LOEs. The company also lays the groundwork for ....
23 Aug 2022
Bristol-Myers Squibb: Acquisition of Turning Point Therapeutics & Other Developments, Financial Forecasts, DCF & Comparables Valuation, ESG & Other Risks (08/22)
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
Bristol-Myers Squibb: Acquisition of Turning Point Therapeutics & Other Developments, Financial Forecasts, DCF & Comparables Valuation, ESG & Other Risks (08/22)
- Published:
23 Aug 2022 -
Author:
Ishan Majumdar -
Pages:
27
Bristol-Myers has continued its efforts towards expanding its new product range, in-line franchises, pipeline, and carried out critical business growth initiatives. The company’s revenues for the second quarter reached approximately $11.9 billion, up 5% from the same period last year and surpassed Wall Street expectations. This result was fuelled by their in-line and new product portfolio's 16% solid growth, which more than made up for their recent LOEs. The company also lays the groundwork for ....